Beating Down BEA

Recs

17

Following a disappointing fiscal Q3 report in November, BEA Systems (Nasdaq: BEAS) issued an earnings warning in May. Over that period, the stock has fallen 24%, with no apparent catalysts to get it moving in the right direction again.

BEA develops a variety of enterprise-software systems to help with complex things like e-commerce and other business applications. Another big focus is service-oriented architecture (SOA), which involves Web-based approaches to help companies meld information technology (IT) environments.

Yesterday BEA announced its Q1 results; they were fairly lackluster, with revenues up 7% to $345.8 million. Net income was not reported, because of the company's investigation of its options program.

One red flag: a 13% drop in license revenues, to $114.6 million. This is a key metric for software companies, because these revenues generally lead to future maintenance and service fees.

Why the drop? Management blamed a weaker IT climate and iffy sales execution. While BEA made some adjustments to its sales force, those changes may have a limited impact if the enterprise software market truly softens.

Despite the slow growth, BEA has a core business of large clients, including Citigroup (NYSE: C), FedEx (NYSE: FDX), Genentech (NYSE: DNA), Verizon (NYSE: VZ), and Procter & Gamble (NYSE: PG). Players like these mean prodigious cash flows, to the tune of $95.1 million in Q1. BEA has about $1.3 billion in the bank.

So it's no surprise that management is focusing on stock buybacks. It's added $500 million to its buyback program, for a total of $620 million.

Still, there are few signs of growth here. The Q2 forecast calls for revenue of $353 million to $367 million, and license revenue of $113 million to $128.5 million. That means the license shortfall could be as much as 16% year over year.

The long-term prospects for SOA look bright, but its deployments can be expensive and time-consuming. BEA also faces intense competition from players such as IBM (NYSE: IBM), and Oracle (Nasdaq: ORCL). Amid a more tepid spending environment, BEA will likely continue its sluggish ways.

Further not-so-BEAutiful Foolishness:

Fool contributor Tom Taulli, author of The Complete M&A Handbook, does not own shares mentioned in this article. FedEx is aMotley Fool Stock Advisor pick. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 528162, ~/Articles/ArticleHandler.aspx, 11/10/2009 7:24:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Health-Care Reform: A Tale of Two Chambers

Related Tickers

11/9/2009 4:01 PM
PG $61.85 Up +0.81 +1.33%
The Procter & Gamb… CAPS Rating: *****
ORCL $21.83 Up +0.41 +1.91%
Oracle Corp. CAPS Rating: ****
FDX $81.22 Up +4.10 +5.32%
FedEx Corp CAPS Rating: ***
IBM $126.00 Up +2.51 +2.03%
International Busi… CAPS Rating: ***
C $4.19 Up +0.13 +3.20%
Citigroup, Inc. CAPS Rating: **
DNA $94.97 Down +0.00 +0.00%
Genentech, Inc. CAPS Rating: ****

Community: Investing Wiki

Term Of The Hour

Biotechnology: Biotechnology uses biological processes to solve problems in such areas as health and medicine, agriculture and manufacturing.

Want to learn more or edit this definition?
Click here to read more!